Innovative Medicine
-
New STELARA® Five-Year Data Show Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
Findings from the Only Psoriasis Clinical Development Program for a Biologic Following Patients Continuously for Five Years Provide Insights on STELARA Long-Term Response and Safety Profile -
New Phase 3 Data Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis
Treatment with STELARA Also Resulted in Significant Improvements in Physical Function, Enthesitis and Dactylitis, and Plaque Psoriasis -
New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease
Study Findings Include Results of SIMPONI Intravenous Formulation on Rheumatoid Arthritis Associated Fatigue -
ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA Plus Prednisone -
-
-
Janssen Healthcare Innovation Announces Discharge Decision Support System (D2S2) Winner of the Janssen Connected Care Challenge
$100,000 award to advance commercialization of D2S2 transition care solution designed to deliver better patient care and reduce hospital readmissions -
-
New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults with Moderately To Severely Active Ulcerative Colitis
First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment